ReviewCurrent neurology and neuroscience reports2014
Microenvironmental clues for glioma immunotherapy.
Review in Current neurology and neuroscience reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Research hotspots and trend of glioblastoma immunotherapy: a bibliometric and visual analysis.Frontiers in oncology · 2024Pooled it
- Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers.Brain sciences · 2026Review
- Immunophenotypic Profile of Adult Glioblastoma IDH-Wildtype Microenvironment: A Cohort Study.Cancers · 2024Article
- Spatial oncology: Translating contextual biology to the clinic.Cancer cell · 2024Review
- Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma.Apoptosis : an international journal on programmed cell death · 2024Article
- Article
- T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10.Nature communications · 2022Observational
- Large-scale bulk RNA-seq analysis defines immune evasion mechanism related to mast cell in gliomas.Frontiers in immunology · 2022Article
- The Interplay of Four Main Pathways Recomposes Immune Landscape in Primary and Metastatic Gastroenteropancreatic Neuroendocrine Tumors.Frontiers in oncology · 2022Article
- Prognostic value and immune cell infiltration of hypoxic phenotype-related gene signatures in glioblastoma microenvironment.Journal of cellular and molecular medicine · 2020Article
- Glioma escape signature and clonal development under immune pressure.The Journal of clinical investigation · 2020Article
- Review
- Article
- HLA-E expression in diffuse glioma: relationship with clinicopathological features and patient survival.BMC neurology · 2020Article
- Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ.Frontiers in immunology · 2020Article
- Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.Science translational medicine · 2019Article
- Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma.Nature communications · 2019Article
- Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas.Frontiers in genetics · 2019Article
- Vaccine Strategies in Gliomas.Current treatment options in neurology · 2018Review
- Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.Journal of neuro-oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas have been viewed for decades as inaccessible for a meaningful antitumor immune response as they grow in a sanctuary site protected from infiltrating immune cells. Moreover, the glioma microenvironment constitutes a hostile environment for an efficient antitumor immune response as glioma-derived factors such as transforming growth factor β and catabolites of the essential amino acid tryptophan paralyze T-cell function. There is growing evidence from preclinical and clinical studies that a meaningful antitumor immunity exists in glioma patients and that it can be activated by vaccination strategies. As a consequence, the concept of glioma immunotherapy appears to be experiencing a renaissance with the first phase 3 randomized immunotherapy trials entering the clinical arena. On the basis of encouraging results from other tumor entities using immunostimulatory approaches by blocking endogenous T-cell suppressive pathways mediated by cytotoxic T-lymphocyte antigen 4 or programmed cell death protein 1/programmed cell death protein 1 ligand 1 with humanized antibodies, there is now a realistic and promising option to combine active immunotherapy with agents blocking the immunosuppressive microenvironment in patients with gliomas to allow a peripheral antitumor immune response induced by vaccination to become effective. Here we review the current clinical and preclinical evidence of antimicroenvironment immunotherapeutic strategies in gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.